Pfizer Ventures — 2026 Investments
4 investments dated 2026 · listed companies and verified rows first · show all
Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Alexander Nolte(Executive Officer)inDmitri Wiederschain(Executive Officer)in
BoardAlexandra Cantley(Director)inSakae Asanuma(Director)inBriggs Morrison(Executive Officer, Director, Promoter)inIrena Melnikova(Director)in
Co-investorsMPM BioImpactPfizer Venture InvestmentsPolaris PartnersTaiho Ventures, LLC
Flare provides software infrastructure and operational support for emergency response teams in government and private sectors, enabling real-time resource management, location tracking, and coordination across multiple agencies to improve response times and effectiveness.
Enterprise SoftwareGovTechSaaSNairobi, KE
Co-investors4Di CapitalInovia CapitalAgent CapitalBase10 PartnersCasdin CapitalInvus+3 more
Flare is a layer 1 blockchain designed for data-intensive decentralized applications, providing enshrined data protocols and infrastructure for developers building with on-chain data.
Crypto & Web3Data & Infrastructure
Co-investorsDigital Currency GroupAgent CapitalBase10 PartnersCasdin CapitalInovia CapitalInvus+3 more
Flare develops AI-driven systems to manage essential workers—such as drivers, cleaners, security guards, and domestic workers—in emerging markets, vertically integrating its technology platform, worker staffing (via subsidiary Drive-Z), and customer implementation.
AI & Machine LearningFuture of WorkHR TechTokyo, JP
Kazuki Kamiya(CEO)Satoru Ichihara(COO)Shinya Hayashi(CSO)Hidefumi Iwaki(CFO)Tomohiro Sasaki(Executive Officer (Product Development))
Co-investorsANOBAKACARTA VENTURES, Inc.Spiral VenturesAgent CapitalBase10 PartnersCasdin Capital+5 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.